Search
(S)-Warfarin
go.drugbank.com/drugs/DB14055InvestigationalWarfarin consists of a racemic mixture of two active enantiomers—R- and S- forms—each of which is cleared by different pathways.
Jaktinib
go.drugbank.com/drugs/DB17545InvestigationalJaktinib is a JAK 1, JAK 2 and JAK 3 inhibitor, being developed by Suzhou Zelgen Biopharmaceuticals.
IDM-1
go.drugbank.com/drugs/DB05292ExperimentalIt is comprised of MAK(Monocytes-derived Activated Killer) cells associated with MDX-210, a bispecific anti-HER-2/neu antibody developed by Medarex Inc.
Glucose-6-Phosphate
go.drugbank.com/drugs/DB03581ExperimentalAn ester of glucose with phosphoric acid, made in the course of glucose metabolism by mammalian and other cells.
TMC-310911
go.drugbank.com/drugs/DB15623Investigational[L12045,A191643] TMC-310911 is currently being investigated, in combination with other HIV therapies and antivirals, as a potential treatment for COVID-19 caused by SARS-CoV-2.[L12012] … TMC-310911 (also known as ASC-09) is a novel investigational protease inhibitor (PI) that is structurally similar to the currently available [darunavir].
Pyrazinamide
go.drugbank.com/drugs/DB00339ApprovedInvestigationalA pyrazine that is used therapeutically as an antitubercular agent.
T-5224
go.drugbank.com/drugs/DB05998ExperimentalT-5224 is an investigational drug developed to treat Sepsis-induced Acute Kidney Injury. It's mechanism of action is to inhibit c-Fos/activator protein-1.
AVR-RD-02
go.drugbank.com/drugs/DB17650InvestigationalAVR-RD-02 is an investigational _ex vivo_ lentiviral gene therapy developed by AVROBIO Inc. … It consists of autologous CD34+ enriched hematopoietic stem cells (HSCs) that have been genetically modified _ex vivo_ with a lentiviral vector (LV) to contain a ribonucleic acid (RNA) transcript that,
Rocatinlimab
go.drugbank.com/drugs/DB18809InvestigationalThe drug works by targeting the OX40 receptor, which plays a role in the immune response associated with atopic dermatitis. … In clinical trials, it has shown significant efficacy and safety compared to a placebo.
AV-COVID-19
go.drugbank.com/drugs/DB15802InvestigationalThe vaccine was developed and tested by Aivita Biomedical, Inc.. As of July 2020, the company is pursuing an adaptive Phase IB-II Randomized Clinical Trial (NCT04386252) to test the vaccine. … The monocytes are then differentiated in vitro into dendritic cells with IL-4 and GM-CSF, incubated with SARS-CoV-2 antigens prior to administration.